Syschem India Q1FY27 net loss widens to ₹1.85 crore on forex volatility

Syschem (India) Limited Syschem reported a net loss of ₹1.85 crore for the quarter ended June 30, 2026, reversing its profitability stance from the same period last year. The company posted an income from operations of ₹12,598.47 lakh, a marginal decline from ₹12,676.35 lakh in Q1FY25. This operational dip contributed to a pre-tax loss of ₹145.24 lakh, compared to a profit of ₹167.35 lakh in the corresponding quarter of the previous fiscal year. The widening loss is primarily attributed to significant fluctuations in foreign exchange rates and heightened volatility in global financial markets arising from ongoing geopolitical and economic uncertainties.

The Board of Directors approved the unaudited financial results at their meeting held on August 4, 2026. The figures were reviewed by the Audit Committee and subsequently examined by the Statutory Auditors in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that segment reporting under Indian Accounting Standard 108 is not applicable as it operates solely in the pharmaceutical products (API) segment.

Financial Performance Metrics

The following table outlines the key financial indicators for Syschem (India) Limited for Q1FY27 compared to previous periods:

Particulars	Q1FY27 (₹ Lakh)	Q4FY26 (₹ Lakh)	Q1FY26 (₹ Lakh)	FY26 (₹ Lakh)
Income from Operations	12,598.47	24,830.56	12,676.35	65,464.70
Profit/(Loss) Before Tax	(145.24)	560.12	167.35	1,478.73
Net Profit/(Loss) After Tax	(184.80)	560.12	167.35	1,092.90
EPS (Basic & Diluted)	-0.31	0.40/0.31	0.38	2.50/1.93

Note: All figures are in Rupees Lakh unless specified otherwise.

Operational Context and Strategic Outlook

Despite the decline in revenue, the company maintained strong operational efficiency through disciplined cost management, optimized production planning, and effective strategic execution. Continued focus on operational excellence, prudent resource utilization, and customer engagement enabled the company to sustain business continuity. Management highlighted that core business operations remained stable despite near-term challenges.

The company is pursuing growth through dedicated manufacturing expansion for Amoxicillin, Cloxacillin sodium, Flucloxacillin sodium, and Dicloxacillin sodium plants. Additionally, Syschem is focused on achieving WHO-GMP certification to strengthen global quality standards and regulatory compliance. The workforce has grown significantly, bringing together experienced professionals to support these initiatives.

What the Numbers Show

The shift from profit to loss in Q1FY27 highlights margin pressure despite relatively stable revenue levels compared to the previous year. While income from operations remained nearly flat YoY, the bottom line deteriorated significantly. EBITDA moderated sharply to ₹38 lakh in Q1FY27 from ₹247 lakh in Q1FY26 and ₹551 lakh in Q4FY26. This divergence between stable revenue and collapsing operating profit indicates that the losses are driven by non-operational factors, specifically foreign exchange fluctuations, rather than a collapse in core demand or pricing power. The full year FY26 saw a net profit of ₹1,092.90 lakh, suggesting that the current quarter's performance is an outlier against the broader annual trend.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.83%	-21.74%	-19.85%	-37.20%	-28.20%	+268.01%

Syschem (India) Limited reported a standalone net loss of ₹166.80 lakh for the quarter ended June 30, 2026, marking a significant reversal from the ₹167.35 lakh profit recorded in the same period of FY25. The deterioration in profitability was driven by a 1.9% increase in total expenses to ₹12,744.70 lakh, despite revenue from operations remaining largely flat at ₹1,259.48 lakh against ₹1,267.58 lakh in Q1FY25. This operational pressure resulted in a pre-tax loss of ₹145.24 lakh, compared to a pre-tax profit of ₹167.35 lakh in the prior year quarter.

The Board of Directors approved these unaudited financial results on August 04, 2026. The statutory auditor, Stav & Co., issued a limited review report on the financial statements in accordance with Standard on Review Engagement (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the Board addressed the forfeiture of upfront consideration linked to lapsed convertible warrants, impacting the company’s capital structure disclosures.

Financial Performance Overview

The following table highlights the key financial metrics for Syschem (India) Limited for the quarter ended June 30, 2026:

Metric	Q1FY26 (₹ Lakh)	Q1FY25 (₹ Lakh)	Change
Revenue from Operations	1,259.48	1,267.58	-0.6%
Total Income	1,259.95	1,267.64	-0.6%
Total Expenses	12,744.70	12,509.00	+1.9%
Profit Before Tax	-145.24	167.35	Turned Negative
Net Profit/Loss	-166.80	167.35	Turned Negative
EPS (Basic/Diluted)	-0.31	0.38	Declined

Note: Figures are in ₹ Lakh unless otherwise specified.

Warrant Lapse and Forfeiture

In a separate development, the Board disclosed the lapse of convertible warrants allotted on a preferential basis on February 04, 2025. The company had allotted 16.7 million warrants, entitling holders to convert them into equity shares within 18 months. The final date for exercise was August 03, 2026.

As allottees failed to exercise their conversion options within the stipulated period, 3.19 million warrants lapsed. Consequently, the company forfeited the upfront amount of ₹39.17 lakh (₹3,91,69,375), which represented 25% of the issue price received at the time of allotment. This forfeiture was disclosed under Regulation 30 of the SEBI (LODR) Regulations, 2015. The specific allottees who failed to convert included Dinesh Jagdishchandra Khokhani, Mahesh J Khokhani, and Mehul Jagadishchandra Khokhani.

What the Numbers Show

The shift from profitability to a net loss in Q1FY26 was driven by an expansion in total expenses rather than a decline in top-line revenue. While gross revenue remained stable year-on-year, total expenses rose by approximately 1.9%, primarily due to higher other expenses (₹577.02 lakh vs ₹134.92 lakh) and employee benefits (₹404.20 lakh vs ₹191.34 lakh). Other income saw a significant increase to ₹4.66 lakh from ₹0.52 lakh in the previous year, but this was insufficient to offset the operational cost pressures. The basic earnings per share fell to -₹0.31 from ₹0.38 in Q1FY25, reflecting the impact of the net loss on shareholder value for the period.